









Mold-Casted Non-Degradable, Islet Macro-encapsulating Hydrogel Devices for 
Restoration of Normoglycemia in Diabetic Mice†  
Rios, Peter Daniela,b, Zhang, Xiaominc, Luo, Xunrongd, Shea, Lonnie D.a,e,f,g,h,i * 
a Simpson Querrey Institute for BioNanotechnology in Medicine, Northwestern University, 
303 East Superior Street, Chicago, IL 60611, USA 
b Department of Biomedical Engineering, Northwestern University, 2145 Sheridan Rd / E310, 
Evanston, IL 60208, USA 
c Department of Surgery, Division of Transplantation, Feinberg School of Medicine, 
Northwestern University, 320 East Superior Street, Chicago, IL 60611, USA 
d Division of Nephrology and Hypertension, Department of Medicine, Northwestern 
University Feinberg School of Medicine, 320 East Superior Street, Chicago, IL 60611, USA 
e Department of Chemical and Biological Engineering, Northwestern University, 2145 
Sheridan Rd / E136, Evanston, IL 60208, USA  
f Chemistry of Life Processes Institute, Northwestern University, Evanston, IL 60208, USA 
g The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 303 East 
Superior Street, Chicago, IL 60611, USA 
h. Department of Obstetrics and Gynecology, Northwestern University, 205 East Superior 
Street, Chicago, IL 60611, USA 
i. Department of Biomedical Engineering, University of Michigan, 1119 Carl A. Gerstacker 
Building, 2200 Bonisteel Boulevard, Ann Arbor, MI 48109-2099 
 
† This article has been accepted for publication and u ergone full peer review but has not been through the 
copyediting, typesetting, pagination and proofreading process, which may lead to differences between this 
version and the Version of Record. Please cite this art cle as doi: [10.1002/bit.26005] 
 
Additional Supporting Information may be found in the online version of this article. 
 
Received   ; Revised 01 May 2016; Accepted    
Biotechnology and Bioengineering 










* Corresponding author.  
Peter Daniel Rios, MS, peterdrios@gmail.com, 757-329 5106 
Xiaomin Zhang, MD, x-zhang@northwestern.edu,  
Xunrong Luo, MD, xunrongluo@northwestern.edu,  












Islet transplantation is a potential cure for diabetic patients, however this procedure is 
not widely adopted due to the high rate of graft failure. Islet encapsulation within hydrogels is 
employed to provide a three-dimensional microenvironment conducive to survival of 
transplanted islets to extend graft function. Herein, we present a novel macroencapsulation 
device, composed of PEG hydrogel, that combines encapsulation with lithography techniques 
to generate polydimethylsiloxane (PDMS) molds. PEG solutions are mixed with islets, which 
are then cast into PDMS molds for subsequent crosslinking. The molds can also be employed 
to provide complex architectures, such as microchannels that may allow vascular ingrowth 
through pre-defined regions of the hydrogel. PDMS molds allowed for the formation of stable 
gels with encapsulation of islets, and in complex architectures. Hydrogel devices with a 
thickness of 600 µm containing 500 islets promoted normoglycemia within 12 days following 
transplantation into the epididymal fat pad, which was sustained over the two-month period of 
study until removal of the device. The inclusion of microchannels, which had a similar 
minimum distance between islets and the hydrogel surface, similarly promoted 
normoglycemia. A glucose challenge test indicated hydrogel devices achieved 
normoglycemia 90 minutes post-dextrose injections, similar to control mice with native 
pancreata. Histochemical staining revealed that transpl nted islets, identified as insulin 
positive, were viable and isolated from host tissue at 8 weeks post-transplantation, yet devices 
with microchannels had tissue and vascular ingrowth wi in the channels. Taken together, 
these results demonstrate a system for creating non-degradable hydrogels with complex 
geometries for encapsulating islets capable of resto ing normoglycemia, which may expand 
islet transplantation as a treatment option for diabetic patients.  
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Islet transplantation is a potential cure for type 1 diabetes (T1D) and, relative to 
exogenous insulin delivery, may provide better control over blood glucose levels. Although 
insulin injections promote normoglycemia in patients with T1D, significant morbidity remains 
as complications such as heart disease, kidney failure, and blindness despite advances in 
insulin delivery technologies (Gibly et al., 2011; Gruessner and Gruessner, 2013). Islet 
transplantation has emerged as an experimental therpy in which islets are delivered into the 
hepatic sinusoids. This strategy has enabled insulin independence for some patients(Ryan et 
al., 2005), and has the potential to avoid the complications associated with insulin therapy. 
However, insulin independence is transient and this procedure is reserved for a subset of T1D 
patients, particularly those with severe glycemic variability and recurrent hypoglycemia, due 
to factors such as a limited islet supply, poor engraftment post-transplantation, and the host 
immune response (Gibly et al., 2011). 
Islets have been encapsulated within biomaterials as a means to protect cells from the 
challenges associated with transplantation (Gibly et al., 2011). Biomaterials are used at 
extrahepatic sites, which avoid the negative effects of the instant blood-mediated 
inflammatory response (IBMIR) that is associated with hepatic transplantation. Encapsulation 
of islets within biomaterials has been investigated to protect the islets from direct contact with 
immune cells, with the goal of educing or eliminatg the use of immunosuppressive drugs. 
While encapsulation aims to prevent contact with host cells, they also impose mass transport 
limitations that can influence the exchange of necessary factors such as glucose, insulin, and 
oxygen and other nutrients (Beck et al., 2007; O’Sullivan et al., 2011; Scharp and Marchetti, 
2013; Vaithilingam and Tuch, 2011). The encapsulating materials have commonly been 
formulated as microcapsules that are delivered into the peritoneal cavity, with exposure to 
oxygen levels that are typically less than in the vasculature (Colton, 2014). Microcapsules 
formed from alginate have been widely used for islet encapsulation with efficacy 









alginate hydrogels and their various modifications, such as poly-L-lysine to control 
permeability, have the potential for fibrotic overgrowth, which can impose additional mass 
transport limitations that can limit islet function ver time following transplantation (Scharp 
and Marchetti, 2013). Recent studies with polyethylene glycol (PEG) based hydrogels or 
coatings for cell transplantation, and particularly is et transplantation, have minimal foreign 
body response and a demonstrated ability to support islet engraftment and function (Jeong et 
al., 2013; Kizilel et al., 2010; Liu et al., Park et al., 2015; Phelps et al., 2013; Rengifo et al., 
2014). 
Macroencapsulation devices are also being developed that minimize contact with the 
host cells, yet provide the opportunity to better control the site at which the islets are 
transplanted. Macroencapsulation systems have been cr ated in various forms, such as 
preformed polymer membranes, or hollow fibers (Buder et al., 2013; Colton, 2014; Song and 
Roy, 2015). These devices are often loaded with a high density of cells, which can impose 
mass transport challenges. To address the mass tranport limitations, these devices may have 
complex geometries that allow for vascular growth near to the islets (O’Sullivan et al., 2011; 
Scharp and Marchetti, 2013). These systems have often been pre-formed and islets are 
subsequently loaded into the devices, which can be retri vable.  
In this report, we investigated the feasibility of using PEG hydrogels to incorporate 
islets at the time that the macroencapsulating device is formed. A non-degradable hydrogel 
was employed to encapsulate islets and isolate themfro  the host cells. PDMS molds are 
formed by photolithography, and the multi-arm PEG/islet mixture is cast into the mold and 
subsequently crosslinked. Molds were employed to create PEG hydrogel slabs, or slabs with 
microchannels that can support tissue ingrowth in defined regions among the islets. Adhesion 
ligands were also incorporated to support the survival of encapsulated islets. (Papavasiliou et 
al., 2005; Pinkse et al., 2006; Weber et al., 2007; Weber and Anseth, 2008). Devices were 









mice. These studies investigated islet engraftment and function using a syngeneic islet 
transplant model, in order to demonstrate the feasibility of the approach and provide a 
foundation for future studies with allogeneic and xenogeneic islets. Taken together, these 
studies determine the feasibility of this encapsulation device as a means to efficiently 
encapsulate islets and isolate them from host tissue.  
2. Materials and Methods 
2.1 Master mold fabrication 
Silicon wafers (3-inch, WRS Materials) were cleaned an  coated evenly with 3.25 g of 
SU8-100 photoresist (MicroChem). Wafers were then pr -baked on a hot plate overnight. A 
photomask (CAD Art Services) was aligned with the potoresist-coated wafer using the 
Q4000 mask aligner (Quintel, NU Materials Processing a d Microfabrication Facility). UV 
exposure of 1400 seconds was then applied to the wafer using the mask aligner to imprint 
photomask features on the photoresist. Wafers were th n post-baked overnight and residual 
photoresist was removed, or “developed”, using 300 mL of polyethylene monomethyl ether 
acetate (Sigma) on a laboratory shaker for 1 hour. An additional 30-minute wash with fresh 
polyethylene monomethyl ether acetate was used to ensur  all residual photoresist was 
removed from the resulting master mold.  
2.2 PDMS mold fabrication 
A Sylgard 184 Silicone Elastomer Kit (Dow Corning) was used in conjunction with 
the master mold to form a PDMS mold. Briefly, 25 g of silicone elastomer base from the kit 
was mixed with 2.5 g of curing agent for 5 minutes (10:1 ratio of elastomer base: curing 
agent). The master mold was then placed in a petri dish (150 x 15mm) and the elastomer 
base/curing agent solution was poured over the master mold. The petri dish was then covered 
and placed in a vacuum for 2 hours to remove air bubbles from the elastomer base/curing 
agent solution. The dish was then transferred to a 60°C oven overnight. The PDMS mold was 









microchannels. PDMS mold outer dimensions were 7.7 mm x 7.7 mm with a 1 mm x 1 mm 
border. For molds to create microchannels, the PDMS inner pattern structure contained ~200 
µm x 200-µm posts spaced 500 µm apart.  
2.3 Hydrogel preparation and macroenapsulation devices formed within PDMS molds  
PEG-maleimide (4-arm, 10kDa MW, JenKem Technology USA) was suspended in 
HEPES Buffer (pH 7.2) and functionalized with 2.5 mM CGRGDS (CelTek Peptides) via 
Michael-Type addition for 30 minutes at 37°C. The concentration of adhesion peptide (2.5 
mM) was chosen such that the number of cysteines corresponds to 6.25% of the number of 
maleimide groups on PEG. Following addition of functionalized PEG precursor solution to 
the PDMS mold, approximately 10 µL of media containing islets were transferred to the 
PDMS mold using a glass transfer pipette. Islets were then mixed into the PEG precursor 
solution to ensure an even distribution within the mold. Next, a YKNR non-degradable 
crosslinker solution, GCYKNRGCYKNRCG (custom synthesis and purification by CelTek 
Peptides), which contained tyrosine (Y) and asparagine (N) amino acids in the D-
configuration, was added in the PDMS mold at a 1:1.1 ratio (remaining mol maleimide: mol 
cysteine) to initiate gel formation. Specifically, the 3-cysteine crosslinking peptide 
(GCYKNRCGYKNRCG) was added at a concentration of 14 mM to crosslink the PEG 
through the unreacted maleimide groups. The crosslinker was added dropwise at multiple 
locations in the PDMS mold. The components (islets, PEG-functionalized with CGRGDS, 
and crosslinker) had to be added in this manner to allow casting within the PDMS, as attempts 
to mix all components in one solution and subsequently deposit within the mold were 
unsuccessful due to the rapid gelation of the PEG. The specific configuration of the Y and N 
amino acids renders the crosslinker peptide as non-degradable because it is not cleavable by 
plasmin. The ability of this tri-cysteine peptide crosslinker, versus a di-cysteine peptide 
crosslinker, to rapidly and efficiently crosslink 4-arm PEG was confirmed in a study by 









al., 2008) or thiolated agents (Kharkar et al., 2015) can be utilized to initiate gel formation 
and control degradation. Gels were then incubated at 37°C for 5 minutes to facilitate 
crosslinking via Michael-Type addition. Molds contai ing crosslinked gels were immediately 
submersed in media supplemented with 10% fetal bovine serum for 3-5 minutes prior to 
transplantation. The resulting macroencapsulation devices were carefully removed from the 
mold using a spatula. Final gels were ~30 µL in volume and 10% PEG wt %. Gels without 
mirochannels were formed in a similar manner, in a PDMS mold.  
2.4 Hydrogel swelling and mesh size experiments 
 After hydrogel formation, samples were immediately weighed to obtain the mass prior 
to swelling. Gels were then swelled overnight in PBS and weighed to determine the mass after 
swelling. Samples were then rinsed in DI water for 4 hours to remove excess salts and 
lyophilized to determine the dry mass. The Flory-Rehner model was then used to calculate the 
hydrogel mesh size (Zustiak et al., 2010).  
2.5 Viability Assessment  
A Live/Dead assay (ThermoFischer Scientific), based on membrane integrity, was 
used to assess islet viability. In brief, 20 µL of 2 mM ethidium homodimer-1 and 5 µL of 4 
mM calcein AM were added to 10 mL of sterile PBS to make a Live/Dead reagent stock. The 
stock was then vortexed to ensure proper mixing. A sample of 50 freshly isolated islets was 
either placed in a 48-culture well (unencapsulated or “free” islets) with HBSS 1X media 
(supplemented with 10% FBS) or encapsulated in a 30 µL hydrogel using the gelation 
conditions specified, and subsequently submersed in media in the well plate. After removal of 
media in the well, 500 µL of the Live/Dead stock solution was added to the samples and 
allowed to incubate for 30 mins at 37°C prior to imaging. 
 









Islets were isolated from healthy 10-12 week old male C57BL/6J (Jackson 
Laboratories) following standard islet isolation procedures. Male C57BL/6J recipient mice 
were between 16-18 weeks of age. Four days prior to islet transplantation, recipient mice were 
injected with 220mg/kg of streptozotocin (Sigma) to chemically induce irreversible diabetes. 
Nonfasting blood glucose levels were taken using a OneTouch Basic Glucose Monitor 
(Aviva) and only those mice with a measurement of 300 mg/dL or greater on consecutive 
days (day before and day of transplant) were used a recipients. Macroencapsulation hydrogel 
devices were formed in PDMS molds with approximately 1,000 islets in each gel. Upon 
removal from the mold, the hydrogel device was cut into 4 equal quadrants with each 
quadrant containing ~250 islets. Each mouse received on  gel quadrant per fat pad (left and 
right fat pad), a total of 500 islets/mouse. The hydrogel device was transplanted into the fat 
pad using the same procedure as reported previously for scaffold implantation (Blomeier et al., 
2006).The fat pad transplantation site allows for a minimally invasive surgery and access to 
vasculature to support islet engraftment as demonstrated in previous studies from our lab 
(Blomeier et al., 2006; Gibly et al., 2011; Salvay et al., 2008). Thus, this site is a feasible site 
for clinical translation and is analogous to the human omentum. All studies were approved by 
the Northwestern University Animal Care and Use Committee. 
2.7 Intraperitoneal glucose tolerance test 
Intraperitoneal glucose tolerance tests (IPGTTs) were p rformed at 8 weeks post-
transplantation to assess the ability of the hydrogel device to respond to glucose challenges. 
After a 3 hour fast period, 2 g/kg of 50% dextrose (Abbott Labs, Chicago, IL) was injected 
intraperitoneally. Blood glucose levels were measured at baseline (before injection), 15, 30, 
60, 90, 120, and 150 minutes after the dextrose injection. Statistical testing for area under the 
curve was performed with a one-way ANOVA and Bonferroni’s Multiple Comparison Post-









2.8 Immunohistochemistry        
 Histological sections were stained with primary antibodies guinea pig polyclonal anti-
swine insulin (Jackson Labs), CD31 (Life Technologies), and Hoechst (Invitrogen) at 
dilutions 1:250, 1:500, 1:2000, respectively. Secondary antibodies included Dylight donkey 
anti-guinea pig 488 (Jackson Labs) and AlexaFluor 555 goat anti-rat (Invitrogen) at a dilution 
of 1:400 and 1:500, respectively.  
2.9 Histology 
Upon device removal, fat pad samples containing hydrogel devices were placed in 4% 
PFA overnight. Samples were then submersed in sucroe/PBS solutions and sucrose 
concentration was progressively increased over a 2-d y period. Devices were then embedded 
in OCT containing 30% sucrose and stored in -80°C until sectioning. Sections were stained 
with hematoxylin and eosin (H&E) to assess cellular ing owth into microchannels of the 
hydrogel device. A picrosirius red stain kit (Abcam), a connective tissue stain, was used 
according to manufacturer instructions to evaluate fibrosis at the hydrogel-adipose tissue 
interface.  
3. Results 
3.1 Macroencapsulating PEG hydrogels with microchannels 
A non-degradable, PEG hydrogel macroencapsulation device with microchannels was 
developed using microfabrication techniques. A 4-arm PEG macromer was initially 
functionalized with 2.5 mM CGRGDS in order to provide sites for cell adhesion, and this 
functionalized PEG was crosslinked using a non-degradable, three-cysteine-containing 
peptide (GCYKNRGCYKNRCG). This peptide is non-degradable as the tyrosine (Y) and 
asparagine (N) amino acids were in the D-form. Hydrogel devices were composed of a final 
PEG content of 10% by weight. This percentage was the lowest concentration that formed 
stable hydrogels after 5 minutes of crosslinking. Note that 5% PEG hydrogels could readily be 









PDMS affects the ability to efficienty mix the crosslinking reagents, which necessitated the 
use of greater PEG concentrations. The microchannel structure was consistently maintained 
upon removal of 10% PEG gels from PDMS molds. The components of this device and their 
concentration are summarized in Table 1. 
Microchannels throughout defined regions of the hydrogel were subsequently 
incorporated to allow for cell and blood vessel ingrowth that would minimize diffusion 
distances. Hydrogels with microchannels were formed by casting the functionalized PEG and 
peptide crosslinker solution inside a PDMS mold. Hydrogels without microchannels (Figure 
1A) were also formed in a PDMS mold. The PDMS mold was created using a photomask and 
standard photolithography techniques (Figure 1B). The mold created hydrogels that were 7.7 
mm x 7.7 mm (length x width), and a thickness of approximately 600 µm. Microchannel 
diameters of ~ 200 µm were readily observed within t e hydrogel device (Figure 1C, 1D) and 
the spacing between the edges of the microchannels was 500 µm (800 µm from center to 
center of microchannel). For the slab devices and devices with microchannels, the maximum 
distance to the edge of the hydrogel was approximately 300 µm. This spacing was maintained 
between both hydrogel forms in order to isolate the impact of more complex molds on the 
hydrogel properties and their ability to support islet function. For hydrogels with 
microchannels, islets were observed to be 204± 1 µm (± SEM, n=17) from a pore edge on 
average, a distance that is consistent with the effective diffusion of oxygen and nutrients from 
capillaries to neighboring cells (Wilson and Chaikof, 2009). Furthermore, swelling 
experiments were performed on 10% hydrogels with microchannels to determine mesh size. A 
mesh size of 9.3 ± 0.3 nm (± SEM, n=3) was calculated using the Flory-Rehner model 
(Zustiak et al., 2010), which is sufficient for transport of insulin and nutrients and consistent 










Islets could be readily encapsulated within the hydrogel. Islets were suspended within 
the RGD-functionalized PEG solution, mixed thoroughly, and then laid into the PDMS mold. 
The YKNR crosslinker solution was then added dropwise at multiple locations in the mold, 
and the mold was then placed in an incubator (37°C) for 5 minutes for gel crosslinking. After 
incubation, islets were identified throughout the hydrogel device and fully encapsulated with 
minimal to no protrusion from the hydrogel (Figure 1E). The distribution of islets between the 
quadrants was investigated through counting of multiple quadrants, which confirmed similar 
islet numbers per quadrant despite some groups of aggregated islets in the gel (Fig 1F). Prior 
to transplantation, islet viability was confirmed using the specified gelation conditions. 
Encapsulated islet viability within the bulk hydrogels post-gelation was assessed using a 
live/dead stain. Encapsulated islets remained viable fter hydrogel formation, with viability 
similar to that observed with islets cultured on tissue culture polystyrene (Figure 2). Taken 
together, this encapsulation approach resulted in an even distribution of islets among the 
hydrogels, with retention of viability.  
3.2 Islet transplantation into diabetic mice       
The engraftment and function of encapsulated islets was investigated by transplanting 
hydrogel-encapsulated islets into mice that were made diabetic by injection of streptozotocin 
(STZ). To accommodate the size of the vascularized fat pad transplant site (Figure 3A), gel 
devices were sectioned into quadrants (~ 4 mm x 4 mm) prior to implantation and each fat pad 
received one-hydrogel quadrant (Figure 3B). Devices remained intact after 2 months post-
transplant and were easily identified in the fat pad (Figure 3C).  
Mice transplanted with hydrogel slabs (without microchannels) containing 500 islets 
achieved consistent normal blood glucose levels (< 200 mg/dL) within two weeks post-
transplantation, as early as Day 11 post-transplant (188 ± 58 mg/dL)(Figure 4A). Mice 
transplanted with hydrogels with microchannels achieved stable normoglycemia at Day 12 









normoglycemia over the two-month period of the study. Upon graft removal at Day 60, all 
mice quickly reverted to a diabetic state within 2-4 days, which confirmed maintenance of 
blood glucose levels was due to the hydrogel graft and not remaining endogenous islets 
(Figure 4A-B). Transplantation of hydrogels containing 300 islets resulted in euglycemia for 
25% of the mice, suggesting that 300 islets is an insufficient mass for this system (Figure 4C).  
An intraperitoneal glucose tolerance test (IPGTT) was performed on mice receiving 
500 islets to investigate glucose responsiveness of encapsulated islets in the PEG hydrogels, 
with or without microchannels (Figure 5A). The blood glucose levels of both experimental 
groups and control mice peaked after 15 minutes post-injection. At 30 and 60 minute time 
points, blood glucose levels mice continued to decrease toward normoglyemia. At 90 minutes, 
all groups achieved normoglycemic levels (~200 mg/dL) and their blood glucose continued to 
decrease for the remainder of timepoints. Area under the curve (AUC) analysis indicated that 
mice which received hydrogels with encapsulated islets, with or without microchannels, were 
not statistically different compared to control mice with native pancreata (p = 0.12, Figure 
5B). 
3.3 Histological analysis of hydrogel implants  
Hydrogel devices removed at 8-weeks post-transplant were sectioned and stained with 
insulin and a Hoechst nuclear counterstain to confirm their presence and functionality post-
encapsulation in vivo. Encapsulated islets stained positive for insulin and were clearly 
identified across graft samples (Figure 6A-D). Islets were observed to be surrounded by the 
hydrogel and were not in contact with the host tissue. These results indicate encapsulated 
islets maintained their morphology, viability, and function in the non-degradable hydrogels. 
Explanted hydrogels, with and without microchannels, were analyzed histologically 
for cellular infiltration around the implant and vascularization within the microchannel 
regions of the hydrogel. H&E staining confirmed cellular growth was confined to the 









in both gel groups (Figure 7A-B). For hydrogels with microchannels, the cell distribution 
around the hydrogel exterior was similar to the hydrogels without microchannels, yet cellular 
infiltration was observed in the microchannels (Figure 7C). Histological staining identified 
CD31-positive cells within the microchannels, consistent with the opportunity of directing 
vascular growth through defined regions of the hydrogel (Figure 7B-C). Collectively, 
histological results suggest this microchannel archite ture can direct vascular growth among 
the transplanted islets and may be a parameter to fu ther investigate to reduce the number of 
encapsulated islets needed to achieve normoglycemia. Furthermore, picrosirius red staining 
indicated no significant fibrotic overgrowth as confirmed by thin layers of connective tissue at 
the gel-adipose tissue interface in both experimental groups (Figure 8).  
4. Discussion 
In this report, we demonstrated the feasibility of n n-degradable PEG hydrogels as a 
macroencapsulation device to encapsulate 500 pancreatic islets and restore normoglycemia in 
diabetic mice over a 2-month period using the peritoneal fat transplantation site. Rodent 
studies with unencapsulated murine islets in other transplantation sites, such as the liver and 
the renal subcapsule, have achieved euglyecmia with lower islet numbers (~ 200-300 islets). 
Additional sites such as subcutaneous and the intraperitoneum have used comparable numbers 
of encapsulated islets to achieve normoglycemia, 500-800 and 750-800 islets, respectively 
(Merani et al., 2008). The encapsulation system provides the opportunity to isolate the 
transplated islets from direct contact with the host tis ue, and can allow for rretrieval of the 
transplanted islets. The approach investigated herein mploys hydrogel encapsulation that has 
been implemented with numerous microencapsulation srategies, yet also creates a 3D 
implantable structure that aims to create a defined sit  in vivo for cell delivery. Among the 
hydrogels employed for encapsulation, alginate microcapsules are the most common, which 
have demonstrated engraftment and function in rodent models with transplantation of islets 









have demonstrated function for much longer times (d Souza et al., 2011). However, alginate 
microcapsules have had limited efficacy in larger animal models (Buder et al., 2013; de Souza 
et al., 2011). Approaches to minimize mass transport limitations have included coating of 
islets with non-adhesive polymers, or islet-loaded microcapsules with a minimal volume of 
alginate and procedures are continuing to be refined to provide stable coatings and to prevent 
a fibrotic overgrowth with the capsule (Jang et al., 2004; Safley et al., 2008)..
 Microcapsules 
have most commonly been delivered into the peritoneal cavity, which can be challenging due 
to the relatively low oxygen concentrations relative to that observed in the pancreas. To avoid 
oxygen deprivation and limited access to nutrients, the hydrogel devices utilized in this study 
were transplanted into the fat pad, a highly vascularized site, to promote survival of 
encapsulated islets. 
In contrast to microencapsulation, a macroencapsulation device is implanted to a 
defined site with the objective of modulating the environment to enhance islet survival and 
function. Numerous in vitro based studies have demonstrated that PEG hydrogels can provide 
a controllable 3D environment that supports islet survival and function. (Lin et al., 2009; Su et 
al., 2010; Weber et al., 2007; Weber and Anseth, 2008). A degradable PEG hydrogel (5% 
w/v), in conjunction with localized delivery of vascular endothelial growth factor (VEGF), 
has been reported to support the in vivo survival and function of transplanted islets following 
implantation into the mesentary, with normalization of blood glucose levels by day 24 (Liao 
et al., 2013; Phelps et al., 2013). Herein we report on the use of non-degradable PEG 
hydrogels (10% w/v) for cell transplantation, and demonstrate normalization of blood glucose 
levels by day 12 with transplantation into the epididymal fat pad. A 10% PEG hydrogel was 
employed, as a lower percentage of PEG would not form well within the PDMS mold, though 
gels could be formed with lower PEG percentages if formed outside of the mold. The 
epididymal fat pad implantation site, relative to the mesentery, may improve islet survival 









studies. Glucose tolerance tests demonstrated a return to normoglycemia within 90 minutes, 
which is consistent with or superior to many encapsulating hydrogels (Dang et al., 2013; de 
Souza et al., 2011; Yun Lee et al., 2007). The use of non-degradable gels was aimed at future 
studies with allogeneic transplantation, in which the adaptive immune cells can be excluded 
from contacting the islets. The penetration of inflammatory cytokines into the gel will 
ultimately need to be addressed, for which multiple reports have indicated the potential for 
modifying PEG with peptides or antibodies against key inflammatory cytokines, such as TNF-
α (Lin et al., 2009; Su et al., 2010).
 
Many macroencapsulation devices have complex architectures to support vascular 
growth among the transplanted islets, while excluding immune cells. Devices, such as 
Theracyte, have been implanted to promote vascularization of the device, with islets loaded 
through a port at later times (Kumagai-Braesch et al., 2013; Qi, 2014). Similarly, the Sernova 
pouch is pre-vascularized prior to delivery of islet  through channels that are opened in the 
device (Qi, 2014). Herein, we demonstrated that PDMS casting can be employed to create 
devices with regularly spaced channels. A previous st dy reported that similarly sized 
micropores permitted mature vascularized tissue formation throughout a porous PEG 
hydrogel (Chiu et al., 2011). The microchanneled hyrogels reported herein demonstrated 
vessel growth through the channels that are near th islets, with the transplanted islets able to 
restore euglycemia. These studies herein focused on the the casting approach and its impact 
on islet survival and function, thus the slab and microchanneled hydrogels had a similar 
minimum diffusion distance, and differences in function were not expected or observed 
between the gel designs. Ongoing studies are focusing on parameters such as channel size and 
spacing for their impact on islet survival and function, which may be important for delivering 
the relatively large mass of islets that are needed clinically. These parameters are of particular 









reduce mass transport limitations. Furthermore, a channeled architecture may be combined 
with the delivery of angiogenic factors to promote a robust vascular network. 
This hydrogel platform had one main mechanism to promote adhesion for islets, 
however bioactive coatings with extracellular matrix proteins can be considered to faciltate 
integration with the host tissue. Extracellular matrix proteins provide structural support and 
bind cell surface integrins that mediate adhesion and activate intracellular signaling pathways 
that promote islet survival. PEG hydrogel devices in th s study were modified with RGD 
peptide, which has been reported to reduce islet apoptosis and support islet function (Weber et 
al., 2007; Weber and Anseth, 2008). The PEG-maleimide used herein had greater 
incorporation efficiencies of RGD and faster gelation kinetics relative to other PEG 
chemistries such as PEG-vinyl sulfone or PEG-acrylate (Phelps et al., 2012). RGD 
modification may also help reduce fibrosis around the hydrogel graft, as PEG modified with 
RGD has been reported to limit the development of fibrotic overgrowth due to activated 
macrophages (Jang et al., 2004). Transplantation of the devices into the peritoneal fat can 
avoid IBMIR that is associated with hepatic delivery, yet the devices can be apposed to the 
blood vessels that are presented throughout the fat pad. Micro- and macroencapsulation 
systems have typically required large masses of islets for transplantation due to poor 
engraftment, (Phelps et al., 2013) and the ability to create architectures that can define 
vascular ingrowth may ultimately provide an opportunity to support this relatively large islet 
mass.  
5. Conclusion                
We present a non-degradable hydrogel-based device and demonstrate the feasibility of 
this approach for long-term function of encapsulated islets in vivo. The microchannel regions 
of the gel permit vascular ingrowth near the islets, however a functional difference was not 
observed in mice that received hydrogel implants wih microchannels. Islet engraftment and 









transplantation. These studies with a syngeneic transpl ntation model provide a foundation for 
future studies with allogeneic and xenogeneic islets. This design can be refined to maximally 
protect the islets and minimize mass transport limitations, and additional modifications are 
possible to modulate the host response at the site of transplantation, which are the focus of 
ongoing studies with allogeneic islet transplantation. 
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